Targeted therapies in Waldenström macroglobulinemia

Current Opinion in Investigational Drugs

Volumn 9, Issue 6, 2008, Pages 631-637

  Burwick, N ^a,b   Roccaro, A M ^a,b   Leleu, X ^a,b   Ghobrial, I M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow microenvironment; Cell signaling; Novel therapeutics; Proteasome; Waldenstr m macroglobulinemia

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENZASTAURIN; EVEROLIMUS; FLUDARABINE; LENALIDOMIDE; MONOCLONAL ANTIBODY; PERIFOSINE; PLERIXAFOR; PR 171; PROTEASOME INHIBITOR; RESVERATROL; RITUXIMAB; SALINOSPORAMIDE A; SGN 70; THALIDOMIDE;

ABSENCE OF SIDE EFFECTS; ANEMIA; APTHOUS ULCER; ARTHRITIS; BLURRED VISION; BRADYCARDIA; CANCER PATIENT; CLINICAL TRIAL; CONFUSION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOCRIT; HEPATOSPLENOMEGALY; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPONATREMIA; LYMPHADENOPATHY; MICROENVIRONMENT; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PNEUMONIA; RASH; REVIEW; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; ULCER; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; THALIDOMIDE; WALDENSTROM MACROGLOBULINEMIA;

EID: 44649085908     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Waldenstrom J: Incipient myelomatosis or 'essential' hyperglobulinemia with fibrinogenopenia - a new syndrome? Acta Med Scand (1944) 117:216-247.
2. Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ: Despite apparent morphologic and immunophenotypic heterogeneity, Waldenström's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol (2003) 30(2):182-186.
3. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis, GA, San Miguel JF, Branagan AR, Dimopoulos MA: Clinicopathological definition of Waldenström's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 30(2):110-115.
4. Herrinton LJ, Weiss NS: Incidence of Waldenström's macroglobulinemia. Blood (1993) 82(10):3148-3150.
5. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin (2005) 55(1):10-30.
6. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O et al: Characterization of familial Waldenström's macroglobulinemia. Ann Oncol (2006) 17(3):488-494.
7. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd: Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol (2003) 30(2):169-171.
8. Ghobrial IM, Gertz MA, Fonseca R: Waldenström macroglobulinaemia. Lancet Oncol (2003) 4(11):679-685.
9. Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J: Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma (2002) 3(3):163-166.
10. Buske C, Dreyling MH, Eimermacher H, Boeck HP, Pfreundschuh M, Metzner B, Fuchs R, Woermann B, Truemper Lh, Hess G, Wandt H et al: Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphoplasmacytoid/ic immunocytoma, results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Blood (ASH Annual Meeting Abstracts) (2004) 104:162.
11. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA; Eastern Cooperative Oncology Group: Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: An Eastern Cooperative Oncology Group Study. Cancer (2004) 101(11):2593-2598.
12. Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Fermand JP et al: Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood (2006) 107(9):3442-3446. •• Consensus panel of experts provide updated treatment recommendations for WM. In particular, this update addresses in detail clinical trials with extended doses of rituximab, combination therapies with standard chemotherapeutic and R-CHOP.
13. Hayashi T et al: Blood (ASH Annual Meeting Abstracts) (2002) 100:4800.
14. Branagan A, Hunter Z, Santos D, Treon SP: Thalidomide and rituximab in Waldenström's macroglobulinemia. Blood (ASH Annual Meeting Abstracts) (2004) 104:1484. • The study design and preliminary results of a thalidomide and rituximab phase II trial in WM are outlined in this abstract. These data are important to review, as it was the first time the strong activity of immunomodulatory drugs in WM was demonstrated. In addition, the researchers discuss important toxicities observed with thalidomide that have led to the investigation of thalidomide analogs as therapeutic agents.
15. Treon SP, patterson CJ, Hunter ZR, Branagan AR: Phase II study of CC-5013 (Revlimid) and rituximab in Waldenström's macroglobulinemia: Preliminary safety and efficacy results. Blood (ASH Annual Meeting Abstracts) (2005) 106:2443. • This abstract reviews the promising efficacy of lenalidomide (revlimid) in WM, but also highlights the unexpected finding of acute hematocrit drop observed in some patients.
16. Adams J: The proteasome: Structure, function, and role in the cell. Cancer Treat Rev (2003) 29(Suppl 1):3-9.
17. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 5(5):417-421.
18. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E, National Cancer Institute of Canada Clinical Trials Group: Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25(12):1570-1575.
19. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA: Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologica (2005) 90(12):1655-1658.
20. Treon SP, Soumerai J, Patterson C, Hunter ZR, Ghobrial IM, Villarreal R, Willen M, Myers T: Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenström's macroglobulinemia, planned interim results of WMCTG clinical trial 05-180. Blood (ASH Annual Meeting Abstracts) (2006) 108:2765.
21. Ghobrial IM, Padmanabhan S, Badros A, Nelson M, Leduc R, Leleu X, Warren D, Soumerai J, Birner A, Schlossman R, Munshi N et al: Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenström macroglobulinemia, preliminary results. Blood (ASH Annual Meeting Abstracts) (2007) 110:4494. •• This phase II trial was designed based on preclinical data showing synergistic activity of bortezomib and rituximab. The preliminary results presented here highlight the encouraging activity of these two drugs in WM when used in combination, as well as the lack of peripheral neuropathy with this regimen.
22. Anderson KC: Bortezomib therapy for myeloma. Curr Hematol Rep (2004) 3(1):65.
23. Chauhan D, Hideshima T, Anderson KC: Proteasome inhibition in multiple myeloma: Therapeutic implication. Annu Rev Pharmacol Toxicol (2005) 45:465-476.
24. O'Connor OA, Orlowski RZ, Alsina M, Stewart K, Trudel S, Vallone MK, Woo TM, Urquilla PR, Molineaux CJ, Goy A: A phase I study to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies. Blood (ASH Annual Meeting Abstracts) (2006) 108:2430.
25. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab B, Burnick N et al: Dual targeting of the proteasome regulates survival and homing in Waldenström's macroglobulinemia. Blood (2008) 111(9):4752-4763. •• This interesting preclinical study demonstrated the potent activity of combination proteasome inhibition in WM, and provides a strong rationale for studying NPI-0052 in this disease.
26. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G et al: The Akt pathway regulates survival and homing in Waldenström macroglobulinemia. Blood (2007) 110(13):4417-4426. •• This preclinical study highlighted the role of Akt upregulation in WM and provided the framework for studying perifosine in WM, and for targeting the Akt pathway in this disease.
27. Ghobrial IM, Leleu X, Rubin N, Nelson M, Leduc R, Warren D, Allen J, Lovecchio S, Soumerai J, Sportelli P, Birch R et al: Phase II trial of perifosine (KRX-0401) in relapsed and/or refractory Waldenström macroglobulinemia: Preliminary results. Blood (ASH Annual Meeting Abstracts) (2007) 110:4493.
28. Ghobrial IM, Leduc R, Nelson M, Leleu X, Jacobsen E, LaCasce A, DeAngelo D, Fisher D, Brown JR, Schlossman R, Warren D et al: Phase II trial of the oral mTOR inhibitor RAD-001 (everolimus) in relapsed and/or refractory Waldenström macroglobulinemia: Preliminary results. Blood (ASH Annual Meeting Abstracts) (2007) 110:4496. • Early preliminary data from seven patients, highlighting the potential activity of mTOR inhibition in WM.
29. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallnian S et al: Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia. Blood (2007) 109(11):4964-4972.
30. Hatjiharissi E, Ho AW, Xu L, O'Connor KE, Hunter ZR, Santos DD, Manning R, Leleu X, Moreau AS, Patterson CJ, McEarchem JA et al: Preclinical in vitro and in vivo evidence support a therapeutic role for the CD70 directed monoclonal antibody (SGN-70) in Waldenström's macroglobulinemia (WM). Blood (ASH Annual Meeting Abstracts) (2006) 108:2490.
31. Lapidot T, Dar A, Kollet O: How do stem cells find their way home? Blood (2005) 106(6):1901-1910.
32. Ngo H, Hatjiharissi E, Leleu X, Runnels J, Moreau AS, Jia X, O'Sullivan G, Santos D, Xu L, Treon S, Hideshima T et al: The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenström macroglobulinemia Blood (ASH Annual Meeting Abstracts) (2006) 108:2418.
33. M, Leleu X, Jia X, Runnels J, Moreau AS, Azab A, Azab F, Hatjiharissi E, Roccaro A, Sacco A et al: The interaction of CXCR4/SDF-1 and VLA-4 regulates adhesion and transendothelial migration in Waldenström macroglobulinemia. Blood (ASH Annual Meeting Abstracts) (2007) 110:2617.
34. Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D et al: Resveratrol exerts anti-proliferative effect and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res (2008) 14(6):1849-1858.